title: [Digital ulcers in systemic scleroderma].
abstract: Digital ulcers (DU's) are one of the main symptoms of systemic scleroderma and occur in approximately 60% of all scleroderma patients. Due to possible complications such as infections, gangrene or amputation, they require regular medical attention and a good wound treatment by doctors and nursing staff. A definition of DU's has not yet been established. In 2009 the European League Against Rheumatism (EULAR) published guidelines for the treatment of DU's. An improvement of the healing of active ulcers has been described with Iloprost. Bosentan significantly reduced the frequency of occurrence of new DU's. In some small studies PDE-5 inhibitors appear helpful. Further studies with other therapeutic approaches will follow in the next few years.
authors.affiliation: Klinik und Poliklinik für Dermatologie und Venerologie, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland, doreen.belz@uk-koeln.de.
authors.forename: D
authors.initials: D
authors.lastname: Belz
authors.forename: N
authors.initials: N
authors.lastname: Hunzelmann
authors.forename: P
authors.initials: P
authors.lastname: Moinzadeh
mesh_terms: D000077300:Bosentan; D005385:Fingers / Q000473:pathology; D006229:Hand Dermatoses / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use*; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D012595:Scleroderma, Systemic / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D012883:Skin Ulcer / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D013449:Sulfonamides; D016285:Iloprost; D000077300:Bosentan